Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-383 Combination Dose Escalation and Expansion in Relapsed/Refractory Multiple Myeloma
jRCT2021220022Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of etentamig in multiple myeloma (MM) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-Limiting Toxicities (DLT). Started Nov 2022; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220022.